Jason Raleigh Nunn Acquires 63,158 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock

Key Points

• Jason Raleigh Nunn, Director of Zenas BioPharma, acquired 63,158 shares of the company at $19.00 each, increasing his total ownership to 1,173,395 shares valued at over $22 million.
• Zenas BioPharma's stock price is currently at $25.85 with a market cap of $1.09 billion, and the company recently reported EPS of ($1.25), missing analyst estimates.
• Several analysts have set contrasting ratings for Zenas BioPharma, with HC Wainwright and Wedbush recommending a "buy" while others, including Wall Street Zen, have downgraded the stock to a "sell".

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) Director Jason Raleigh Nunn bought 63,158 shares of the business's stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average cost of $19.00 per share, with a total value of $1,200,002.00. Following the purchase, the director directly owned 1,173,395 shares in the company, valued at $22,294,505. The trade was a 5.69% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zenas BioPharma Stock Performance

ZBIO stock traded down $0.69 during trading on Tuesday, hitting $25.85. The stock had a trading volume of 415,023 shares, compared to its average volume of 207,008. The company's 50 day moving average price is $19.06 and its two-hundred day moving average price is $13.56. Zenas BioPharma, Inc. has a 1-year low of $5.83 and a 1-year high of $29.73. The stock has a market cap of $1.09 billion and a price-to-earnings ratio of -7.28.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.23).

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Zenas BioPharma in a research note on Thursday, October 9th. Wedbush increased their target price on shares of Zenas BioPharma from $35.00 to $40.00 and gave the stock an "outperform" rating in a research report on Thursday, October 9th. Wall Street Zen downgraded shares of Zenas BioPharma from a "hold" rating to a "sell" rating in a research report on Friday, September 26th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Zenas BioPharma in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $38.33.

Hedge Funds Weigh In On Zenas BioPharma

Several institutional investors and hedge funds have recently made changes to their positions in ZBIO. New York State Common Retirement Fund purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at approximately $49,000. Jefferies Financial Group Inc. purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at approximately $348,000. Nuveen LLC purchased a new position in shares of Zenas BioPharma during the 1st quarter valued at approximately $250,000. PNC Financial Services Group Inc. boosted its stake in shares of Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company's stock valued at $89,000 after buying an additional 2,679 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Zenas BioPharma by 4.6% during the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after buying an additional 16,461 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.